Potential roles of selenium and selenoproteins in the prevention of alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 16, Issue 8, 2016, Pages 835-848

  Du, Xiubo ^a   Wang, Chao ^b   Liu, Qiong ^a  

^a SHENZHEN UNIVERSITY   (China)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Alzheimer s disease (AD); Amyloid ; Metal; Oxidative stress; Selenium (Se); Selenoprotein; Signal transduction; Tau

Indexed keywords

MAPT PROTEIN, HUMAN; MOLECULAR LIBRARY; SELENIUM; SELENIUM DERIVATIVE; SELENOPROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR LIBRARY; OXIDATIVE STRESS; PHARMACOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; HUMANS; OXIDATIVE STRESS; SELENIUM; SELENIUM COMPOUNDS; SELENOPROTEINS; SMALL MOLECULE LIBRARIES; TAU PROTEINS;

EID: 84984799261     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150827094936     Document Type: Article

References (155)

1. Goedert, M.; Spillantini, M. G., A century of Alzheimer's disease. Science, 2006, 314 (5800), 777-781.
2. Woo, H. N.; Park, J. S.; Gwon, A. R.; Arumugam, T. V.; Jo, D. G., Alzheimer's disease and Notch signaling. Biochem. Biophys. Res. Commun., 2009, 390(4), 1093-1097.
3. Mattson, M. P., Pathways towards and away from Alzheimer's disease. Nature, 2004, 430 (7000), 631-639.
4. Walsh, D. M.; Selkoe, D. J., Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein. Pept. Lett., 2004, 11(3), 213-228.
5. Selkoe, D. J.; Podlisny, M. B., Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics. Hum. Genet., 2002, 3, 67-99.
6. Mandelkow, E. M.; Mandelkow, E., Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Csh. Perspect. Med., 2012, 2(7), a006247.
7. Arriagada, P. V.; Growdon, J. H.; Hedley-Whyte, E. T.; Hyman, B. T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 1992, 42(3 Pt 1), 631-639.
8. Bancher, C.; Braak, H.; Fischer, P.; Jellinger, K. A., Neuropa-thological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett., 1993, 162(1-2), 179-182.
9. Polydoro, M.; Acker, C. M.; Duff, K.; Castillo, P. E.; Davies, P., Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci., 2009, 29(34), 10741-10749.
10. Small, S. A.; Duff, K., Linking A beta and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis. Neuron., 2008, 60(4), 534-542.
11. Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G., Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem. Rev., 2006, 106(6), 1995-2044.
12. Adlard, P. A.; Bush, A. I., Metals and Alzheimer's disease. J. Alz-heimers. Dis., 2006, 10(2-3), 145-163.
13. Gao, S. J.; Jin, Y. L.; Hall, K. S.; Liang, C. K.; Unverzagt, F. W.; Ma, F.; Cheng, Y. B.; Shen, J. Z.; Cao, J. X.; Matesan, J.; Li, P.; Bian, J. C.; Hendrie, H. C.; Murrell, J. R. Selenium level is associated with apoE epsilon 4 in rural elderly Chinese. Public. Health. Nutr., 2009, 12(12), 2371-2376.
14. Hwang, D. Y., Cho, J. S., Oh, J. H., Shim, S. B., Jee, S. W., Lee, S. H., Seo, S. J., Lee, S. K., Lee, S. H., and Kim, Y. K., Differentially expressed genes in transgenic mice carrying human mutant preseni-lin-2 (N141I): Correlation of selenoprotein M with Alzheimer's disease. Neurochem. Res., 2005, 30(8), 1009-1019.
15. Wenstrup, D.; Ehmann, W. D.; Markesbery, W. R., Trace-Element Imbalances in Isolated Subcellular-Fractions of Alzheimers-Disease Brains. Brain. Res., 1990, 533(1), 125-131.
16. Burk, R. F.; Hill, K. E., Selenoprotein P-expression, functions, and roles in mammals. Biochim. Biophys. Acta., 2009, 1790(11), 1441-1447.
17. Kryukov, G. V.; Castellano, S.; Novoselov, S. V.; Lobanov, A. V.; Zehtab, O.; Guigo, R.; Gladyshev, V. N., Characterization of mammalian selenoproteomes. Science, 2003, 300(5624), 1439-1443.
18. Ninomiya, M.; Garud, D. R.; Koketsu, M., Biologically significant selenium-containing heterocycles. Coordin. Chem. Rev., 2011, 255(23-24), 2968-2990.
19. Hatfield, D. L.; Tsuji, P. A.; Carlson, B. A.; Gladyshev, V. N., Selenium and selenocysteine: roles in cancer, health, and develop-ment. Trends. Biochem. Sci., 2014, 39(3), 112-120.
20. Loscalzo, J. Keshan disease, selenium deficiency, and the seleno-proteome. New. Engl. J. Med., 2014, 370 (18), 1756-1760.
21. Song, G.; Zhang, Z.; Wen, L.; Chen, C.; Shi, Q.; Zhang, Y.; Ni, J.; Liu, Q., Selenomethionine ameliorates cognitive decline, reduces tau hyperphosphorylation, and reverses synaptic deficit in the triple transgenic mouse model of Alzheimer's disease. J. Alzheimers. Dis., 2014, 41(1), 85-99.
22. Yakubov, E.; Buchfelder, M.; Eyupoglu, I. Y.; Savaskan, N. E., Selenium Action in Neuro-Oncology. Biol. Trace. Elem. Res., 2014, 161(3), 246-254.
23. Qi, Y. F.; Fu, X. Q.; Xiong, Z. G.; Zhang, H. T.; Hill, S. M.; Rowan, B. G.; Dong, Y., Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer. Plos One, 2012, 7(2).
24. Wen, Z. Y.; Xu, J. W.; Wang, Z. W.; Qi, H.; Xu, Q. L.; Bai, Z. S.; Zhang, Q.; Bao, K.; Wu, Y. L.; Zhang, W. G.; 3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: Microwave-assisted synthesis and bio-logical evaluation. Eur. J. Med. Chem., 2015, 90, 184-194.
25. Janakiram, N. B.; Mohammed, A.; Ravillah, D.; Choi, C. I.; Zhang, Y. T.; Desai, D.; Amin, S.; Rao, C. V., Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. Onco. Rep., 2013, 30(2), 952-960.
26. Manna, D.; Roy, G.; Mugesh, G., Antithyroid Drugs and Their Analogues: Synthesis, Structure, and Mechanism of Action. Ac-counts. Chem. Res., 2013, 46(11), 2706-2715.
27. Huang, X.; Liu, X. M.; Luo, Q. A.; Liu, J. Q.; Shen, J. C., Artificial selenoenzymes: Designed and redesigned. Chem. Soc. Rev., 2011, 40(3), 1171-1184.
28. Luo, G. M.; Ren, X. J.; Liu, J. Q.; Mu, Y.; Shen, J. C., Towards more efficient glutathione peroxidase mimics: Substrate recogni-tion and catalytic group assembly. Curr. Med. Chem., 2003, 10(13), 1151-1183.
29. Huang, X.; Yin, Y. Z.; Liu, J. Q., Design of Artificial Selenoen-zymes Based on Macromolecular Scaffolds. Macromol. Biosci., 2010, 10(12), 1385-1396.
30. Wu, Z. P.; Hilvert, D., Selenosubtilisin as a Glutathione-Peroxidase Mimic. J. Am. Chem. Soc., 1990, 112 (14), 5647-5648.
31. Yim, S. Y.; Chae, K. R.; Shim, S. B.; Hong, J. T.; Park, J. Y.; Lee, C. Y.; Son, H. J.; Sheen, Y. Y.; Hwang, D. Y., ERK activation induced by selenium treatment significantly downregulates beta/gamma-secretase activity and Tau phosphorylation in the transgenic rat overexpressing human selenoprotein M. Int. J. Mol. Med., 2009, 24(1), 91-96.
32. Lovell, M. A.; Xiong, S. L.; Lyubartseva, G.; Markesbery, W. R., Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free. Radical. Bio.Med., 2009, 46(11), 1527-1533.
33. Haratake, M.; Yoshida, S.; Mandai, M.; Fuchigami, T.; Nakayama, M., Elevated amyloid-beta plaque deposition in dietary selenium-deficient Tg2576 transgenic mice. Metallomics, 2013, 5(5), 479-483.
34. Zamberlan, D. C.; Arantes, L. P.; Machado, M. L.; Golombieski, R.; Soares, F. A. A., DIPHENYL-DISELENIDE SUPPRESSES AMYLOID-beta PEPTIDE IN CAENORHABDITIS ELEGANS MODEL OF ALZHEIMER'S DISEASE. Neuroscience, 2014, 278, 40-50.
35. Deng, Z. Q.; Fu, H. J.; Xiao, Y. M.; Zhang, B.; Sun, G. S.; Wei, Q.; Ai, B. M.; Hu, Q. S., Effects of selenium on lead-induced alterations in A beta production and Bcl-2 family proteins. Environ. Toxicol. Phar., 2015, 39(1), 221-228.
36. Wei, D.; Chen, T.; Yan, M.; Zhao, W.; Li, F.; Cheng, W.; Yuan, L., Synthesis, characterization, antioxidant activity and neuroprotec-tive effects of selenium polysaccharide from Radix hedysari. Car-bohyd. Polym., 2015, 125, 161-168.
37. Chen, L.; Na, R.; Gu, M.; Richardson, A.; Ran, Q., Lipid peroxida-tion up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J. Neurochem., 2008, 107(1), 197-207.
38. Ran, Q.; Gu, M.; Van Remmen, H.; Strong, R.; Roberts, J. L.; Richardson, A., Glutathione peroxidase 4 protects cortical neurons from oxidative injury and amyloid toxicity. J. Neurosci. Res., 2006, 84(1), 202-208.
39. Lovell, M. A.; Xie, C.; Gabbita, S. P.; Markesbery, W. R., Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free. Radic. Biol. Med., 2000, 28(3), 418-427.
40. Hoffmann, P. R.; Hoge, S. C.; Li, P. A.; Hoffmann, F. W.; Hashi-moto, A. C.; Berry, M. J., The selenoproteome exhibits widely varying, tissue-specific dependence on selenoprotein P for selenium supply. Nucleic. Acids. Res., 2007, 35(12), 3963-3973.
41. Burk, R. F.; Hill, K. E., Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeo-stasis. Annu. Rev. Nutr., 2005, 25, 215-235.
42. Lu, T.; Pan, Y.; Kao, S. Y.; Li, C.; Kohane, I.; Chan, J.; Yankner, B. A., Gene regulation and DNA damage in the ageing human brain. Nature, 2004, 429(6994), 883-891.
43. Rueli, R. H., Parubrub, A. C., Dewing, A. S., Hashimoto, A. C., Bellinger, M. T., Weeber, E. J., Uyehara-Lock, J. H., White, L. R., Berry, M. J., and Bellinger, F. P., Increased selenoprotein p in choroid plexus and cerebrospinal fluid in Alzheimer's disease brain. J. Alzheimers. Dis., 2015, 44(2), 379-383.
44. Bellinger, F. P.; He, Q. P.; Bellinger, M. T.; Lin, Y.; Raman, A. V.; White, L. R.; Berry, M. J., Association of selenoprotein p with Alzheimer's pathology in human cortex. J. Alzheimers. Dis., 2008, 15(3), 465-472.
45. Takemoto, A. S.; Berry, M. J.; Bellinger, F. P., Role of selenopro-tein P in Alzheimer's disease. Ethn. Dis., 2010, 20(1 Suppl 1), S1-92-95.
46. Hill, K. E.; Zhou, J.; McMahan, W. J.; Motley, A. K.; Burk, R. F., Neurological dysfunction occurs in mice with targeted deletion of the selenoprotein P gene. J. Nutr., 2004, 134(1), 157-161.
47. Caito, S. W.; Milatovic, D.; Hill, K. E.; Aschner, M.; Burk, R. F.; Valentine, W. M., Progression of neurodegeneration and morphol-ogic changes in the brains of juvenile mice with selenoprotein P de-leted. Brain. Res., 2011, 1398, 1-12.
48. Reeves, M. A.; Bellinger, F. P.; Berry, M. J., The neuroprotective functions of selenoprotein M and its role in cytosolic calcium regu-lation. Antioxid. Redox. Sign, 2010, 12(7), 809-818.
49. Chen, P.; Wang, R. R.; Ma, X. J.; Liu, Q.; Ni, J. Z., Different Forms of Selenoprotein M Differentially Affect Abeta Aggregation and ROS Generation. Int. J. Mol. Sci., 2013, 14(3), 4385-4399.
50. Chen, P.; Wang, C.; Ma, X.; Zhang, Y.; Liu, Q.; Qiu, S.; Liu, Q.; Tian, J.; Ni, J., Direct Interaction of Selenoprotein R with Clusterin and Its Possible Role in Alzheimer's Disease. PLoS One, 2013, 8(6), e66384.
51. DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A., Aronow, B. J., Bales, K. R., Paul, S. M., and Holtzman, D. M., ApoE and clusterin coopera-tively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron, 2004, 41(2), 193-202.
52. Bramblett, G. T.; Goedert, M.; Jakes, R.; Merrick, S. E.; Troja-nowski, J. Q.; Lee, V. M., Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron, 1993, 10(6), 1089-1099.
53. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y. C.; Quinlan, M.; Wis-niewski, H. M.; Binder, L. I., Abnormal phosphorylation of the mi-crotubule-associated protein tau (tau) in Alzheimer cytoskeletal pa-thology. Proc. Natl. Acad. Sci. USA, 1986, 83(13), 4913-4917.
54. Gong, C. X.; Singh, T. J.; Grundke-Iqbal, I.; Iqbal, K., Phosphopro-tein phosphatase activities in Alzheimer disease brain. J. Neuro-chem., 1993, 61(3), 921-927.
55. Sontag, E.; Luangpirom, A.; Hladik, C.; Mudrak, I.; Ogris, E.; Speciale, S.; White, C. L., 3rd, Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J. Neuropathol. Exp. Neurol., 2004, 63(4), 287-301.
56. Vogelsberg-Ragaglia, V.; Schuck, T.; Trojanowski, J. Q.; Lee, V. M., PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp. Neurol., 2001, 168(2), 402-412.
57. Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C. X., Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci., 2005, 22(8), 1942-1950.
58. Yim, S. Y.; Chae, K. R.; Shim, S. B.; Hong, J. T.; Park, J. Y.; Lee, C. Y.; Son, H. J.; Sheen, Y. Y.; Hwang, D. Y., ERK activation induced by selenium treatment significantly downregulates beta/gamma-secretase activity and Tau phosphorylation in the transgenic rat overexpressing human selenoprotein M. Int. J. Mol. Med., 2009, 24(1), 91-96.
59. Corcoran, N. M.; Martin, D.; Hutter-Paier, B.; Windisch, M.; Nguyen, T.; Nheu, L.; Sundstrom, L. E.; Costello, A. J.; Hovens, C. M., Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J. Clin. Neurosci., 2010, 17(8), 1025-1033.
60. van Eersel, J.; Ke, Y. D.; Liu, X.; Delerue, F.; Kril, J. J.; Gotz, J.; Ittner, L. M., Sodium selenate mitigates tau pathology, neurode-generation, and functional deficits in Alzheimer's disease models. Proc. Natl. Acad. Sci. USA, 2010, 107(31), 13888-13893.
61. Lee, Y. J.; Kim, J. E.; Kwak, M. H.; Go, J.; Yang, S. Y.; Kwon, H. S.; Kim, B. C.; Kim, J. M.; Hwang, D. Y., Selenium treatment significantly inhibits tumor necrosis factor-alpha-induced cell death and tau hyperphosphorylation in neuroblastoma cells. Mol. Med. Rep., 2014, 10(4), 1869-1874.
62. Huang, X.; Moir, R. D.; Tanzi, R. E.; Bush, A. I.; Rogers, J. T., Redox-active metals, oxidative stress, and Alzheimer's disease pa-thology. Ann. NY. Acad. Sci., 2004, 1012, 153-163.
63. Johnson, D. K.; Storandt, M.; Morris, J. C.; Langford, Z. D.; Galvin, J. E., Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology, 2008, 71(22), 1783-1789.
64. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T. D.; Mazur, M.; Telser, J., Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell. B., 2007, 39(1), 44-84.
65. Lippoldt, A.; Padilla, C. A.; Gerst, H.; Andbjer, B.; Richter, E.; Holmgren, A.; Fuxe, K., Localization of Thioredoxin in the Rat-Brain and Functional Implications. J. Neurosci., 1995, 15(10), 6747-6756.
66. Mitsui, A.; Hirakawa, T.; Yodoi, J., Reactive Oxygen-Reducing and Protein-Refolding Activities of Adult T-Cell Leukemia-Derived Factor Human Thioredoxin. Biochem. Bioph. Res. Co., 1992, 186(3), 1220-1226.
67. Rayman, M. P., The importance of selenium to human health. Lancet, 2000, 356(9225), 233-241.
68. Yoon, S. O.; Kim, M. M.; Park, S. J.; Kim, D.; Chung, J.; Chung, A. S., Selenite suppresses hydrogen peroxide-induced cell apopto-sis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways. Faseb. J., 2001, 15(13), 111-113.
69. Williams, T. I.; Lynn, B. C.; Markesbery, W. R.; Lovell, M. A., Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging., 2006, 27(8), 1094-1099.
70. Smith, J. L.; Xiong, S.; Lovell, M. A., 4-hydroxynonenal disrupts zinc export in primary rat cortical cells. Neurotoxicology, 2006, 27(1), 1-5.
71. Tung, Y. T.; Hsu, W. M.; Wang, B. J.; Wu, S. Y.; Yen, C. T.; Hu, M. K.; Liao, Y. F., Sodium selenite inhibits gamma-secretase activity through activation of ERK. Neurosci. Lett., 2008, 440(1), 38-43.
72. Xiong, S. L.; Markesbery, W. R.; Shao, C. X.; Lovell, M. A., Se-leno-L-methionine protects against beta-amyloid and iron/hydrogen peroxide-mediated neuron death. Antioxid. Redox. Sign., 2007, 9(4), 457-467.
73. Kumar, B.; Nahreini, P.; Hanson, A. J.; Andreatta, C.; Prasad, J. E.; Prasad, K. N., Selenomethionine prevents degeneration induced by overexpression of wild-type human alpha-synuclein during differ-entiation of neuroblastoma cells. J. Am. Coll. Nutr., 2005, 24(6), 516-523.
74. Takasago, T.; Peters, E. E.; Graham, D. I.; Masayasu, H.; Macrae, I. M., Neuroprotective efficacy of ebselen, an anti-oxidant with an-tiinflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Brit. J. Pharmacol., 1997, 122(6), 1251-1256.
75. Porciuncula, L. O.; Rocha, J. B. T.; Boeck, C. R.; Vendite, D.; Souza, D. O., Ebselen prevents excitotoxicity provoked by gluta-mate in rat cerebellar granule neurons. Neurosci. Lett., 2001, 299(3), 217-220.
76. Imai, H.; Graham, D.; Masayasu, H.; Macrae, I. M., Neuroprotec-tive efficacy of an intravenous formulation of ebselen in a rodent model of focal ischaemia. Brain. Pathol., 2000, 10(4), 563-563.
77. Yamaguchi, T.; Sano, K.; Takakura, K.; Saito, I.; Shinohara, Y.; Asano, T.; Yasuhara, H.; Grp, E. S., Ebselen in acute ischemic stroke-A placebo-controlled, double-blind clinical trial. Stroke, 1998, 29(1), 12-17.
78. Zimmerman, M. T.; Bayse, C. A.; Ramoutar, R. R.; Brumaghim, J. L., Sulfur and selenium antioxidants: challenging radical scaveng-ing mechanisms and developing structure-activity relationships based on metal binding. J. Inorg. Biochem., 2015, 145, 30-40.
79. Garcia, T.; Esparza, J. L.; Nogues, M. R.; Romeu, M.; Domingo, J. L.; Gomez, M., Oxidative stress status and RNA expression in hip-pocampus of an animal model of Alzheimer's disease after chronic exposure to aluminum. Hippocampus, 2010, 20(1), 218-225.
80. Yoo, M. H.; Gu, X.; Xu, X. M.; Kim, J. Y.; Carlson, B. A.; Patter-son, A. D.; Cai, H.; Gladyshev, V. N.; Hatfield, D. L., Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer's disease. Antioxid. Re-dox. Sign., 2010, 12(7), 819-827.
81. Valentine, W. M.; Abel, T. W.; Hill, K. E.; Austin, L. M.; Burk, R. F., Neurodegeneration in mice resulting from loss of functional se-lenoprotein P or its receptor apolipoprotein E receptor 2. J. Neuro-path. Exp. Neur., 2008, 67(1), 68-77.
82. Holmgren, A.; Lu, J., Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem. Biophys. Res. Commun., 2010, 396(1), 120-124.
83. Arner, E. S., Focus on mammalian thioredoxin reductases--important selenoproteins with versatile functions. Biochim. Bio-phys. Acta., 2009, 1790(6), 495-526.
84. Lu, J.; Holmgren, A., The thioredoxin antioxidant system. Free. Radic. Biol. Med., 2014, 66, 75-87.
85. Loef, M.; Schrauzer, G. N.; Walach, H., Selenium and Alzheimer's disease: a systematic review. J. Alzheimers. Dis., 2011, 26(1), 81-104.
86. Barger, S. W.; Mattson, M. P., Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer's beta-amyloid precursor. Brain. Res. Mol. Brain. Res., 1996, 40(1), 116-126.
87. Camandola, S.; Poli, G.; Mattson, M. P., The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain. Res. Mol. Brain. Res., 2000, 85(1-2), 53-60.
88. Anderson, M. T.; Staal, F. J.; Gitler, C.; Herzenberg, L. A.; Herzenberg, L. A., Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc. Natl. Acad. Sci. USA, 1994, 91(24), 11527-11531.
89. Granic, I.; Dolga, A. M.; Nijholt, I. M.; van Dijk, G.; Eisel, U. L., Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J. Alzheimers. Dis., 2009, 16(4), 809-821.
90. Schenk, H.; Klein, M.; Erdbrugger, W.; Droge, W.; Schulze-Osthoff, K., Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc. Natl. Acad. Sci. USA, 1994, 91(5), 1672-1676.
91. Vunta, H.; Davis, F.; Palempalli, U. D.; Bhat, D.; Arner, R. J.; Thompson, J. T.; Peterson, D. G.; Reddy, C. C.; Prabhu, K. S., The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. J. Biol. Chem., 2007, 282(25), 17964-17973.
92. Christensen, M. J.; Pusey, N. W., Binding of nuclear proteins to transcription regulatory elements in selenium deficiency. Biochim. Biophys. Acta., 1994, 1225(3), 338-341.
93. Brigelius-Flohe, R.; Friedrichs, B.; Maurer, S.; Schultz, M.; Streicher, R., Interleukin-1-induced nuclear factor kappa B activation is inhibited by overexpression of phospholipid hydroperoxide glutathione peroxidase in a human endothelial cell line. Biochem. J., 1997, 328( Pt 1), 199-203.
94. Kretz-Remy, C.; Mehlen, P.; Mirault, M. E.; Arrigo, A. P., Inhibition of I kappa B-alpha phosphorylation and degradation and sub-sequent NF-kappa B activation by glutathione peroxidase overex-pression. J. Cell. Biol., 1996, 133(5), 1083-1093.
95. LaFerla, F. M., Calcium dyshomeostasis and intracellular signal-ling in Alzheimer's disease. Nat. Rev. Neurosci., 2002, 3(11), 862-872.
96. Woods, N. K.; Padmanabhan, J., Neuronal calcium signaling and Alzheimer's disease. Adv. Exp. Med. Biol., 2012, 740, 1193-1217.
97. Camandola, S.; Mattson, M. P., Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim. Bio-phys. Acta., 2011, 1813(5), 965-973.
98. Kuchibhotla, K. V.; Lattarulo, C. R.; Hyman, B. T.; Bacskai, B. J., Synchronous hyperactivity and intercellular calcium waves in as-trocytes in Alzheimer mice. Science, 2009, 323(5918), 1211-1215.
99. Kose, S. A.; Naziroglu, M., Selenium reduces oxidative stress and calcium entry through TRPV1 channels in the neutrophils of patients with polycystic ovary syndrome. Biol. Trace. Elem. Res., 2014, 158(2), 136-142.
100. Naziroglu, M.; Senol, N.; Ghazizadeh, V.; Yuruker, V., Neuropro-tection induced by N-acetylcysteine and selenium against traumatic brain injury-induced apoptosis and calcium entry in hippocampus of rat. Cell. Mol. Neurobiol., 2014, 34(6), 895-903.
101. Okatan, E. N.; Tuncay, E.; Turan, B., Cardioprotective effect of selenium via modulation of cardiac ryanodine receptor calcium re-lease channels in diabetic rat cardiomyocytes through thioredoxin system. J. Nutr. Biochem., 2013, 24(12), 2110-2118.
102. Verma, S.; Hoffmann, F. W.; Kumar, M.; Huang, Z.; Roe, K.; Nguyen-Wu, E.; Hashimoto, A. S.; Hoffmann, P. R., Selenoprotein K knockout mice exhibit deficient calcium flux in immune cells and impaired immune responses. J. Immunol., 2011, 186(4), 2127-2137.
103. Grumolato, L., Ghzili, H., Montero-Hadjadje, M., Gasman, S., Lesage, J., Tanguy, Y., Galas, L., Ait-Ali, D., Leprince, J., Guer-ineau, N. C., Elkahloun, A. G., Fournier, A., Vieau, D., Vaudry, H., and Anouar, Y., Selenoprotein T is a PACAP-regulated gene involved in intracellular Ca2+ mobilization and neuroendocrine se-cretion. FASEB. J., 2008, 22(6), 1756-1768.
104. Jurynec, M. J.; Xia, R.; Mackrill, J. J.; Gunther, D.; Crawford, T.; Flanigan, K. M.; Abramson, J. J.; Howard, M. T.; Grunwald, D. J., Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle. Proc. Natl. Acad. Sci. USA, 2008, 105(34), 12485-12490.
105. Hoozemans, J. J.; van Haastert, E. S.; Nijholt, D. A.; Rozemuller, A. J.; Eikelenboom, P.; Scheper, W., The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocam-pus. Am. J. Pathol., 2009, 174(4), 1241-1251.
106. Alberdi, E.; Wyssenbach, A.; Alberdi, M.; Sanchez-Gomez, M. V.; Cavaliere, F.; Rodriguez, J. J.; Verkhratsky, A.; Matute, C., Ca(2+)-dependent endoplasmic reticulum stress correlates with astroglio-sis in oligomeric amyloid beta-treated astrocytes and in a model of Alzheimer's disease. Aging Cell, 2013, 12(2), 292-302.
107. Kogel, D.; Concannon, C. G.; Muller, T.; Konig, H.; Bonner, C.; Poeschel, S.; Chang, S.; Egensperger, R.; Prehn, J. H., The APP intracellular domain (AICD) potentiates ER stress-induced apoptosis. Neurobiol. Aging., 2012, 33(9), 2200-2209.
108. Resende, R.; Ferreiro, E.; Pereira, C.; Oliveira, C. R., ER stress is involved in Abeta-induced GSK-3beta activation and tau phos-phorylation. J. Neurosci. Res., 2008, 86(9), 2091-2099.
109. Wang, S. Q.; Niu, X. L.; Liu, Z. W.; Zhu, Y. H.; Gao, D. F., Selenium deficiency is associated with endoplasmic reticulum stress in a rat model of cardiac malfunction. Biol. Trace. Elem. Res., 2013, 156(1-3), 196-201.
110. Liu, H.; Li, X.; Qin, F.; Huang, K., Selenium suppresses oxidative-stress-enhanced vascular smooth muscle cell calcification by inhib-iting the activation of the PI3K/AKT and ERK signaling pathways and endoplasmic reticulum stress. J. Biol. Inorg. Chem., 2014, 19(3), 375-388.
111. Shchedrina, V. A.; Zhang, Y.; Labunskyy, V. M.; Hatfield, D. L.; Gladyshev, V. N., Structure-function relations, physiological roles, and evolution of mammalian ER-resident selenoproteins. Antioxid. Redox. Sign., 2010, 12(7), 839-849.
112. Speckmann, B.; Gerloff, K.; Simms, L.; Oancea, I.; Shi, W.; McGuckin, M. A.; Radford-Smith, G.; Khanna, K. K., Selenopro-tein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cells. Free. Radic. Biol. Med., 2014, 67, 265-277.
113. Fradejas, N.; Pastor, M. D.; Mora-Lee, S.; Tranque, P.; Calvo, S., SEPS1 gene is activated during astrocyte ischemia and shows prominent antiapoptotic effects. J. Mol. Neurosci., 2008, 35(3), 259-265.
114. Shchedrina, V. A.; Everley, R. A.; Zhang, Y.; Gygi, S. P.; Hatfield, D. L.; Gladyshev, V. N., Selenoprotein K binds multiprotein com-plexes and is involved in the regulation of endoplasmic reticulum homeostasis. J. Biol. Chem., 2011, 286(50), 42937-42948.
115. Kasaikina, M. V., Fomenko, D. E., Labunskyy, V. M., Lachke, S. A., Qiu, W., Moncaster, J. A., Zhang, J., Wojnarowicz, M. W., Jr., Natarajan, S. K., Malinouski, M., Schweizer, U., Tsuji, P. A., Carl-son, B. A., Maas, R. L., Lou, M. F., Goldstein, L. E., Hatfield, D. L., and Gladyshev, V. N., Roles of the 15-kDa selenoprotein (Sep15) in redox homeostasis and cataract development revealed by the analysis of Sep 15 knockout mice. J. Biol. Chem., 2011, 286(38), 33203-33212.
116. Pinton, S.; da Rocha, J. T.; Zeni, G.; Nogueira, C. W., Organosele-nium improves memory decline in mice: involvement of acetylcho-linesterase activity. Neurosci. Lett., 2010, 472(1), 56-60.
117. Moshtaghie, A. A.; Ani, M.; Aghadavod, E.; Fazilati, M., Protec-tive effects of selenium and zinc on changes in catecholamine levels of brain regions in lead intoxified rat. Pak. J. Biol. Sci., 2007, 10(17), 2964-2967.
118. Han, X. J.; Xiao, Y. M.; Ai, B. M.; Hu, X. X.; Wei, Q.; Hu, Q. S., Effects of organic selenium on lead-induced impairments of spatial learning and memory as well as synaptic structural plasticity in rats. Biol. Pharm. Bull., 2014, 37(3), 466-474.
119. Qian, W.; Miao, K.; Li, T.; Zhang, Z., Effect of selenium on fluo-ride-induced changes in synaptic plasticity in rat hippocampus. Biol. Trace. Elem. Res., 2013, 155(2), 253-260.
120. Godoi, G. L.; de Oliveira Porciuncula, L.; Schulz, J. F.; Kaufmann, F. N.; da Rocha, J. B.; de Souza, D. O.; Ghisleni, G.; de Almeida, H. L., Jr., Selenium compounds prevent amyloid beta-peptide neu-rotoxicity in rat primary hippocampal neurons. Neurochem. Res., 2013, 38(11), 2359-2363.
121. Masliah, E.; Mallory, M.; Alford, M.; DeTeresa, R.; Hansen, L. A.; McKeel, D. W., Jr.; Morris, J. C., Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 2001, 56(1), 127-129.
122. Roselli, F.; Tirard, M.; Lu, J.; Hutzler, P.; Lamberti, P.; Livrea, P.; Morabito, M.; Almeida, O. F., Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glu-tamatergic synapses. J. Neurosci., 2005, 25(48), 11061-11070.
123. Raman, A. V.; Pitts, M. W.; Seyedali, A.; Hashimoto, A. C.; Bel-linger, F. P.; Berry, M. J., Selenoprotein W expression and regulation in mouse brain and neurons. Brain. Behav., 2013, 3(5), 562-574.
124. Bush, A. I., The metallobiology of Alzheimer's disease. Trends. Neurosci., 2003, 26(4), 207-214.
125. Smith, M. A.; Harris, P. L.; Sayre, L. M.; Perry, G., Iron accumula-tion in Alzheimer disease is a source of redox-generated free radi-cals. Proc. Natl. Acad. Sci. USA, 1997, 94(18), 9866-9868.
126. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R., Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci., 1998, 158(1), 47-52.
127. Faller, P.; Hureau, C., Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton. T., 2009, (7), 1080-1094.
128. Sharma, A. K.; Pavlova, S. T.; Kim, J.; Finkelstein, D.; Hawco, N. J.; Rath, N. P.; Mirica, L. M., Bifunctional compounds for control-ling metal-mediated aggregation of the abeta42 peptide. J. Am. Chem. Soc., 2012, 134(15), 6625-6636.
129. Faller, P., Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal-ion transfer. Chembio-chem., 2009, 10(18), 2837-2845.
130. Rauk, A., The chemistry of Alzheimer's disease. Chem. Soc. Rev., 2009, 38 (9), 2698-2715.
131. Halliwell, B.; Gutteridge, J. M., Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J., 1984, 219(1), 1-14.
132. Hegde, M. L., Bharathi, P., Suram, A., Venugopal, C., Jaganna-than, R., Poddar, P., Srinivas, P., Sambamurti, K., Rao, K. J., Scan-car, J., Messori, L., Zecca, L., and Zatta, P., Challenges associated with metal chelation therapy in Alzheimer's disease. J. Alzheimers. Dis., 2009, 17(3), 457-468.
133. Rodriguez-Rodriguez, C., Rodriguez-Rodriguez, C., Sanchez de Groot, N., Rimola, A., Alvarez-Larena, A., Lloveras, V., Vidal-Gancedo, J., Ventura, S., Vendrell, J., Sodupe, M., and Gonzalez-Duarte, P., Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J. Am. Chem. Soc., 2009, 131(4), 1436-1451.
134. Wang, Z.; Wang, Y.; Li, W.; Mao, F.; Sun, Y.; Huang, L.; Li, X., Design, synthesis, and evaluation of multitarget-directed selenium-containing clioquinol derivatives for the treatment of Alzheimer's disease. ACS Chem. Neurosci., 2014, 5(10), 952-962.
135. Du, X.; Zheng, Y.; Wang, Z.; Chen, Y.; Zhou, R.; Song, G.; Ni, J.; Liu, Q., Inhibitory act of selenoprotein P on Cu(+)/Cu(2+)-induced tau aggregation and neurotoxicity. Inorg. Chem., 2014, 53(20), 11221-11230.
136. Du, X.; Wang, Z.; Zheng, Y.; Li, H.; Ni, J.; Liu, Q., Inhibitory effect of selenoprotein P on Cu(+)/Cu(2+)-induced Abeta42 aggregation and toxicity. Inorg. Chem., 2014, 53(3), 1672-1678.
137. Du, X.; Li, H.; Wang, Z.; Qiu, S.; Liu, Q.; Ni, J., Selenoprotein P and selenoprotein M block Zn2+-mediated Abeta42 aggregation and toxicity. Metallomics, 2013, 5(7), 861-870.
138. Dikiy, A., Novoselov, S. V., Fomenko, D. E., Sengupta, A., Carl-son, B. A., Cerny, R. L., Ginalski, K., Grishin, N. V., Hatfield, D. L., and Gladyshev, V. N., SelT, SelW, SelH, and Rdx12: genomics and molecular insights into the functions of selenoproteins of a novel thioredoxin-like family. Biochemistry, 2007, 46(23), 6871-6882.
139. Mutter, J.; Curth, A.; Naumann, J.; Deth, R.; Walach, H., Does Inorganic Mercury Play a Role in Alzheimer's Disease? A Systematic Review and an Integrated Molecular Mechanism. J. Alzheim-ers. Dis., 2010, 22(2), 357-374.
140. Hock, C.; Drasch, G.; Golombowski, S.; Muller-Spahn, F.; Willer-shausen-Zonnchen, B.; Schwarz, P.; Hock, U.; Growdon, J. H.; Nitsch, R. M., Increased blood mercury levels in patients with Alzheimer's disease. J. Neural. Transm., 1998, 105(1), 59-68.
141. Ehmann, W. D.; Markesbery, W. R.; Alauddin, M.; Hossain, T. I. M.; Brubaker, E. H., Brain Trace-Elements in Alzheimers-Disease. Neurotoxicology, 1986, 7(1), 197-206.
142. Palkiewicz, P.; Zwiers, H.; Lorscheider, F. L., ADP-ribosylation of brain neuronal proteins is altered by in vitro and in vivo exposure to inorganic mercury. J. Neurochem., 1994, 62(5), 2049-2052.
143. Olivieri, G.; Novakovic, M.; Savaskan, E.; Meier, F.; Baysang, G.; Brockhaus, M.; Muller-Spahn, F., The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxida-tive stress, neurotoxicity and beta-amyloid secretion. Neuroscience, 2002, 113(4), 849-855.
144. Cuvin-Aralar, M. L.; Furness, R. W., Mercury and selenium inter-action: a review. Ecotox. Environ. Safe., 1991, 21(3), 348-364.
145. Wenstrup, D.; Ehmann, W. D.; Markesbery, W. R., Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain. Res., 1990, 533(1), 125-131.
146. Corrigan, F. M.; Reynolds, G. P.; Ward, N. I., Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals, 1993, 6(3), 149-154.
147. El-Demerdash, F. M., Antioxidant effect of vitamin E and selenium on lipid peroxidation, enzyme activities and biochemical parame-ters in rats exposed to aluminium. J. Trace. Elem. Med. Biol., 2004, 18(1), 113-121.
148. Frisardi, V., Solfrizzi, V., Capurso, C., Kehoe, P. G., Imbimbo, B. P., Santamato, A., Dellegrazie, F., Seripa, D., Pilotto, A., Capurso, A., and Panza, F., Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treat-ment. J. Alzheimers. Dis., 2010, 20(1), 17-30.
149. White, L. D., Cory-Slechta, D. A., Gilbert, M. E., Tiffany-Castiglioni, E., Zawia, N. H., Virgolini, M., Rossi-George, A., Lasley, S. M., Qian, Y. C., and Basha, M. R., New and evolving concepts in the neurotoxicology of lead. Toxicol. Appl. Pharm., 2007, 225(1), 1-27.
150. Braun, J. M.; Kahn, R. S.; Froehlich, T.; Auinger, P.; Lanphear, B. P., Exposures to environmental toxicants and attention deficit hy- peractivity disorder in US children. Environ. Health. Persp., 2006, 114(12), 1904-1909.
151. Gu, H. Y.; Robison, G.; Hong, L.; Barrea, R.; Wei, X.; Farlow, M. R.; Pushkar, Y. N.; Du, Y. S.; Zheng, W., Increased beta-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure. Toxicol. Lett., 2012, 213(2), 211-219.
152. Huang, H.; Bihaqi, S. W.; Cui, L. X.; Zawia, N. H., In vitro Pb exposure disturbs the balance between A beta production and elimination: The role of A beta PP and neprilysin. Neurotoxicology, 2011, 32(3), 300-306.
153. Wang, M.; Fu, H. J.; Xiao, Y. M.; Ai, B. M.; Wei, Q.; Wang, S. Y.; Liu, T.; Ye, L. Q.; Hu, Q. S., Effects of low-level organic selenium on lead-induced alterations in neural cell adhesion molecules. Brain. Res., 2013, 1530, 76-81.
154. Bateman, R. J., Xiong, C. J., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X. Y., Blazey, T. M., Holtzman, D. M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P. S., Ghetti, B., Klunk, W. E., McDade, E., Martins, R. N., Masters, C. L., Mayeux, R., Ringman, J. M., Rossor, M. N., Schofield, P. R., Sperling, R. A., Salloway, S., and Morris, J. C., Clinical and Biomarker Changes in Domi-nantly Inherited Alzheimer's Disease. New. Engl. J. Med., 2012, 367(9), 795-804.
155. Hung, R. J.; Spaeth, C. S.; Yesilyurt, H. G.; Terman, J. R., SelR reverses Mical-mediated oxidation of actin to regulate F-actin dy-namics. Nat. Cell. Biol., 2013, 15(12), 1445-1454.